MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Invited conference paper presented and published in conference proceedings
CUHK Authors
Full Text
Digital Object Identifier (DOI) DOI for CUHK Users View Full-text in Publisher Website |
Altmetrics Information
.
Other information
AbstractBackground
The MD Anderson Precision Oncology Decision Support (PODS) group provides genomic support to clinicians to guide enrollment onto genotype-matched trials through gene annotation and reporting on therapeutic actionability of genomic alterations based on NGS reports. PODS was evaluated in a pilot study (Glo-PODS) at a CUHK-affiliated hospital in Hong Kong.
Methods
Patients with predominantly GI solid tumors who participated in two prospective precision oncology studies (PROCURE, STARTRK) at the CUHK were enrolled. Eligible patients had commercially available NGS panel analysis of their respective tumors. Genomic alterations of their NGS reports were annotated by the PODS to determine therapeutic actionability based on the variant’s known or potential functional and/or therapeutic significance. Data collected: demographics, treatment outcomes and impact
Results
A total of 144 Chinese patients were enrolled from Feb 2020-2023 - primary diagnosis of colorectal 79.2%, gastric/gastroesophageal 4.9%, pancreatic 4.2%, lung 2.1%, endometrial 0.7%, cervical 0.7% & unknown primary 0.7%. NGS reports were derived from 3 different NGS panels. Of the 131 patients data analyzed to date, 1,367 annotations were performed on 902 unique genomic alterations plus TMB and MSI status. Of the 1367 annotations, 395 (28.9%) were actionable, 317 (23.2%) were potentially
Conclusions
Over 50% of genomic alteration annotations were deemed actionable/ potentially actionable by PODS in this cohort of Asian patients with predominantly GI cancers. PODS influenced clinical management in ∼10% of patients, but not trial enrollment. Compared with US experience, our results should be interpreted in the context of differences in cancer-type & clinical trial landscape.
The MD Anderson Precision Oncology Decision Support (PODS) group provides genomic support to clinicians to guide enrollment onto genotype-matched trials through gene annotation and reporting on therapeutic actionability of genomic alterations based on NGS reports. PODS was evaluated in a pilot study (Glo-PODS) at a CUHK-affiliated hospital in Hong Kong.
Methods
Patients with predominantly GI solid tumors who participated in two prospective precision oncology studies (PROCURE, STARTRK) at the CUHK were enrolled. Eligible patients had commercially available NGS panel analysis of their respective tumors. Genomic alterations of their NGS reports were annotated by the PODS to determine therapeutic actionability based on the variant’s known or potential functional and/or therapeutic significance. Data collected: demographics, treatment outcomes and impact
Results
A total of 144 Chinese patients were enrolled from Feb 2020-2023 - primary diagnosis of colorectal 79.2%, gastric/gastroesophageal 4.9%, pancreatic 4.2%, lung 2.1%, endometrial 0.7%, cervical 0.7% & unknown primary 0.7%. NGS reports were derived from 3 different NGS panels. Of the 131 patients data analyzed to date, 1,367 annotations were performed on 902 unique genomic alterations plus TMB and MSI status. Of the 1367 annotations, 395 (28.9%) were actionable, 317 (23.2%) were potentially
Conclusions
Over 50% of genomic alteration annotations were deemed actionable/ potentially actionable by PODS in this cohort of Asian patients with predominantly GI cancers. PODS influenced clinical management in ∼10% of patients, but not trial enrollment. Compared with US experience, our results should be interpreted in the context of differences in cancer-type & clinical trial landscape.
All Author(s) ListMa B, Johnson A, Mills Shaw KR, Loong H, Mo F, Lui R, Wong KH, Zeng Z, Holla V, Kahle M, Vu T, Su F, Kim SH, Conway T, Wang Q, Tao W, Zhou L, Rodon J, Meric-Bernstam F, Yap TA
Name of ConferenceESMO Asia Congress 2023
Start Date of Conference01/12/2023
End Date of Conference03/12/2023
Place of ConferenceSingapore
Country/Region of ConferenceSingapore
Proceedings TitleAnnals of Oncology
Year2023
Month11
Volume Number34
Issue NumberSuppl. 4
Place of PublicationSingapoe
Article number424P
PagesS1629 - S1629
LanguagesEnglish-United Kingdom
